Coherus BioSciences, Inc. logo
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET | Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
22157.jpg
HUMIRA (Adalimumab) Biosimilars Market Report 2021: Current Developer Landscape and Clinical Research Scenario Related to All the Follow-on Products of the Blockbuster Biologic Drug
July 30, 2021 06:03 ET | Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "HUMIRA? (Adalimumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars,...
ScipherTM.png
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
June 15, 2021 08:00 ET | Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
22157.jpg
Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030
March 29, 2021 04:53 ET | Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global...
Coherus BioSciences, Inc. logo
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
February 17, 2021 07:30 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has...
22157.jpg
Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030
February 03, 2021 04:43 ET | Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...
Logo.png
Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight
January 19, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight  ...